Acute Negative Allosteric Modulation of M5 Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on Antinociception
journal contributionposted on 24.07.2019, 19:13 by Robert W. Gould, Barak W. Gunter, Michael Bubser, Robert T. Matthews, Laura B. Teal, Madeline G. Ragland, Thomas M. Bridges, Aaron T. Garrison, Danny G. Winder, Craig W. Lindsley, Carrie K. Jones
Opioid use disorder (OUD) is a debilitating neuropsychiatric condition characterized by compulsive opioid use, dependence, and repeated relapse after periods of abstinence. Given the high risk of developing OUD following prescription opioid use, the continued need for opioid-induced analgesia, and the limitations of current OUD treatments, it is necessary to develop novel, non-opioid-based treatments for OUD and decrease abuse potential of prescription opioids. Recent evidence suggests that negative allosteric modulation (NAM) of the M5 muscarinic acetylcholine receptor (M5 mAChR) may provide an alternative therapeutic approach for the treatment of OUD. Previous studies demonstrated localization of M5 mAChR expression within the mesocorticolimbic reward circuitry and that the selective M5 NAM ML375 attenuates both cocaine and alcohol self-administration in rats. In the present study, the effects of ML375 were evaluated in rats self-administering the μ-opioid agonists oxycodone or remifentanil on a progressive ratio (PR) schedule or on cue reactivity (a rodent model of relapse) in the absence of oxycodone following 72 h of abstinence. ML375 reduced the PR break point for oxycodone and remifentanil self-administration and attenuated cue-elicited responding. Importantly, ML375 did not affect sucrose pellet-maintained responding on a PR schedule or opioid-induced antinociception using the hot-plate and tail-flick assays. We also confirm expression of M5 mAChR mRNA in the ventral tegmental area and show that this is primarily on dopamine (tyrosine hydroxylase mRNA-positive) neurons. Taken together, these findings suggest that selective functional antagonism of the M5 mAChR may represent a novel, non-opioid-based treatment for OUD.
Read the peer-reviewed publication
M 5 muscarinic acetylcholine receptorμ- opioid agonists oxycodoneprescription opioid usePRM 5 mAChRML 375M 5 mAChR mRNAventral tegmental areaM 5 NAM ML 375 attenuatesM 5 mAChR expressiontyrosine hydroxylase mRNA-positiveOUDmesocorticolimbic reward circuitryAntinociception Opioid use disorderM 5 Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration